Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

QNCX holding history

Quince Therapeutics, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

QNCX overviewAll 13F holders of QNCXFull Q2 2026 holdings

Shares (Q2 2026)
4,730
Value
$86.0K
% of portfolio
<0.1%
Quarters held
22
Since Q1 2021
Holdings of QNCX by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20264,730$86.0K<0.1%+4,174+750.7%AddedHolders
Q1 2026556$56<0.1%−34,536−98.4%ReducedHolders
Q4 202535,092$117.6K<0.1%+33,620+2,284.0%AddedHolders
Q3 20251,472$2.40K<0.1%−1,374−48.3%ReducedHolders
Q2 20252,846$4.70K<0.1%+2,140+303.1%AddedHolders
Q1 2025706$939<0.1%−408−36.6%ReducedHolders
Q4 20241,114$2.08K<0.1%+634+132.1%AddedHolders
Q3 2024480$373<0.1%00.0%UnchangedHolders
Q2 2024480$360<0.1%−25−5.0%ReducedHolders
Q1 2024505$536<0.1%00.0%UnchangedHolders
Q4 2023505$530<0.1%−6,163−92.4%ReducedHolders
Q3 20236,668$7.47K<0.1%+5,756+631.1%AddedHolders
Q2 2023912$1.37K<0.1%+587+180.6%AddedHolders
Q1 2023325$507<0.1%−45,544−99.3%ReducedHolders
Q4 202245,869$29.4K<0.1%+12,565+37.7%AddedHolders
Q3 202233,304$44.0K<0.1%+8,181+32.6%AddedHolders
Q2 202225,123$56.0K<0.1%−463−1.8%ReducedHolders
Q1 202225,586$158.0K<0.1%+9,934+63.5%AddedHolders
Q4 202115,652$197.0K<0.1%−1,338−7.9%ReducedHolders
Q3 202116,990$1.56M<0.1%+6,844+67.5%AddedHolders
Q2 202110,146$537.0K<0.1%−25,670−71.7%ReducedHolders
Q1 202135,816$1.29M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.